Daniel E. Falk

4.9k total citations · 2 hit papers
46 papers, 3.0k citations indexed

About

Daniel E. Falk is a scholar working on Epidemiology, Pathology and Forensic Medicine and Cellular and Molecular Neuroscience. According to data from OpenAlex, Daniel E. Falk has authored 46 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Epidemiology, 21 papers in Pathology and Forensic Medicine and 9 papers in Cellular and Molecular Neuroscience. Recurrent topics in Daniel E. Falk's work include Substance Abuse Treatment and Outcomes (36 papers), Alcohol Consumption and Health Effects (21 papers) and Neurotransmitter Receptor Influence on Behavior (9 papers). Daniel E. Falk is often cited by papers focused on Substance Abuse Treatment and Outcomes (36 papers), Alcohol Consumption and Health Effects (21 papers) and Neurotransmitter Receptor Influence on Behavior (9 papers). Daniel E. Falk collaborates with scholars based in United States, Germany and France. Daniel E. Falk's co-authors include Hsiao‐ye Yi, Raye Z. Litten, Susanne Hiller-Sturmhöfel, Joanne B. Fertig, Megan L. Ryan, Henry R. Kranzler, George F. Koob, Raymond F. Anton, Katie Witkiewitz and Raye Z. Litten and has published in prestigious journals such as American Journal of Psychiatry, Neuropsychopharmacology and Addiction.

In The Last Decade

Daniel E. Falk

46 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An epidemiologic analysis of co-occurring alcohol and drug use and disorders: findings from the National Epidemiologic Survey of Alcohol and Related Conditions (NESARC).

2006 523 citations Daniel E. Falk, Hsiao‐ye Yi et al. profile →
Defining Recovery From Alcohol Use Disorder: Development of an NIAAA Research Definition

2022 98 citations Daniel E. Falk, Raye Z. Litten et al. profile →

Peers

Countries citing papers authored by Daniel E. Falk

Since Specialization

Citations

This map shows the geographic impact of Daniel E. Falk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel E. Falk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel E. Falk more than expected).

Fields of papers citing papers by Daniel E. Falk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel E. Falk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel E. Falk. The network helps show where Daniel E. Falk may publish in the future.

Co-authorship network of co-authors of Daniel E. Falk

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel E. Falk. A scholar is included among the top collaborators of Daniel E. Falk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel E. Falk. Daniel E. Falk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Preliminary effects of oral ANS-6637, an ALDH2 inhibitor, on cue-induced craving, safety and alcohol consumption among adults with alcohol use disorder: a proof-of-concept, randomized, human laboratory trial 2025 ·Alcohol and Alcoholism ·Stephanie S. O’Malley, Robert Miranda, Sarah W. Book, Thomas H. Chun, Thomas Liss, Robert Malcolm, Srinivas B. Muvvala, Hayley Treloar Padovano, Joseph P. Schacht, Brent Blackburn, Ivan Diamond, Janet H. Ransom, Megan L. Ryan, Daniel E. Falk, Raye Z. Litten	2
2	Effects of a novel GABA‐B positive allosteric modulator, ASP8062, on alcohol cue‐elicited craving and naturalistic alcohol consumption in a multisite randomized, double‐blind, placebo‐controlled trial 2024 ·Alcohol Clinical and Experimental Research ·Joseph P. Schacht, Lara A. Ray, Robert Miranda, Daniel E. Falk, Megan L. Ryan, Joseph T. Sakai, Karen Miotto, Thomas H. Chun, Charles Scott, Janet H. Ransom, (unknown), (unknown), Raye Z. Litten	2
3	World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom 2020 ·Addiction ·Katie Witkiewitz, Nick Heather, Daniel E. Falk, Raye Z. Litten, Deborah S. Hasin, Henry R. Kranzler, Karl Mann, Stephanie S. O’Malley, Raymond F. Anton	51
4	Reduction in non-abstinent WHO drinking risk levels and depression/anxiety disorders: 3-year follow-up results in the US general population 2019 ·Drug and Alcohol Dependence ·Justin Knox, Jennifer Scodes, Melanie M. Wall, Katie Witkiewitz, Henry R. Kranzler, Daniel E. Falk, Raye Z. Litten, Karl Mann, Stephanie S. O’Malley, Raymond F. Anton, Deborah S. Hasin	40
5	Maintenance of World Health Organization Risk Drinking Level Reductions and Posttreatment Functioning Following a Large Alcohol Use Disorder Clinical Trial 2019 ·Alcoholism Clinical and Experimental Research ·Katie Witkiewitz, Daniel E. Falk, Raye Z. Litten, Deborah S. Hasin, Henry R. Kranzler, Karl Mann, Stephanie S. O’Malley, Raymond F. Anton	43
6	Reduction in Nonabstinent WHO Drinking Risk Levels and Change in Risk for Liver Disease and Positive AUDIT‐C Scores: Prospective 3‐Year Follow‐Up Results in the U.S. General Population 2018 ·Alcoholism Clinical and Experimental Research ·Justin Knox, Melanie M. Wall, Katie Witkiewitz, Henry R. Kranzler, Daniel E. Falk, Raye Z. Litten, Karl Mann, Stephanie S. O’Malley, Jennifer Scodes, Raymond F. Anton, Deborah S. Hasin	51
7	Differences Between Treatment‐Seeking and Nontreatment‐Seeking Alcohol‐Dependent Research Participants: An Exploratory Analysis 2017 ·Alcoholism Clinical and Experimental Research ·(unknown), Mary R. Lee, (unknown), Melanie L. Schwandt, Daniel E. Falk, Lorenzo Leggio	57
8	Advances in Pharmacotherapy Development: Human Clinical Studies 2017 ·Handbook of experimental pharmacology ·Raye Z. Litten, Daniel E. Falk, Megan L. Ryan, Joanne B. Fertig, Lorenzo Leggio	22
9	Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels 2016 ·Alcoholism Clinical and Experimental Research ·Katie Witkiewitz, Kevin A. Hallgren, Henry R. Kranzler, Karl Mann, Deborah S. Hasin, Daniel E. Falk, Raye Z. Litten, Stephanie S. O’Malley, Raymond F. Anton	110
10	An exploratory evaluation of Take Control : A novel computer-delivered behavioral platform for placebo-controlled pharmacotherapy trials for alcohol use disorder 2016 ·Contemporary Clinical Trials ·Eric Devine, Megan L. Ryan, Daniel E. Falk, Joanne B. Fertig, Raye Z. Litten	15
11	A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence 2016 ·Neuropsychopharmacology ·Megan L. Ryan, Daniel E. Falk, Joanne B. Fertig, Beatrice Rendenbach‐Mueller, David A. Katz, Katherine Tracy, Eric C. Strain, Kelly E. Dunn, Kyle M. Kampman, Elizabeth M. Mahoney, Domenic A. Ciraulo, (unknown), Nassima Ait‐Daoud, Bankole A. Johnson, Janet H. Ransom, Charles Scott, George F. Koob, Raye Z. Litten	56
12	Methods to Analyze Treatment Effects in the Presence of Missing Data for a Continuous Heavy Drinking Outcome Measure When Participants Drop Out from Treatment in Alcohol Clinical Trials 2014 ·Alcoholism Clinical and Experimental Research ·Katie Witkiewitz, Daniel E. Falk, Henry R. Kranzler, Raye Z. Litten, Kevin A. Hallgren, Stephanie S. O’Malley, Raymond F. Anton	50
13	A Double-Blind, Placebo-Controlled Trial Assessing the Efficacy of Varenicline Tartrate for Alcohol Dependence 2013 ·Journal of Addiction Medicine ·Raye Z. Litten, Megan L. Ryan, Joanne B. Fertig, Daniel E. Falk, Bankole A. Johnson, Kelly E. Dunn, Alan I. Green, Helen M. Pettinati, Domenic A. Ciraulo, Ofra Sarid‐Segal, Kyle M. Kampman, Mary F. Brunette, Eric C. Strain, Nassima Ait‐Daoud Tiouririne, Janet H. Ransom, Charles Scott, Robert L. Stout	216
14	A Double‐Blind, Placebo‐Controlled Trial Assessing the Efficacy of Levetiracetam Extended‐Release in Very Heavy Drinking Alcohol‐Dependent Patients 2012 ·Alcoholism Clinical and Experimental Research ·Joanne B. Fertig, Megan L. Ryan, Daniel E. Falk, Raye Z. Litten, Margaret E. Mattson, Janet H. Ransom, (unknown), Charles Scott, Domenic A. Ciraulo, Alan I. Green, Nassima Ait‐Daoud Tiouririne, Bankole A. Johnson, Helen M. Pettinati, Eric C. Strain, Eric Devine, Mary F. Brunette, Kyle M. Kampman, D. Andrew Tompkins, Robert L. Stout, (unknown)	43
15	Medications development to treat alcohol dependence: a vision for the next decade 2012 ·Addiction Biology ·Raye Z. Litten, Mark Egli, Markus Heilig, Changhai Cui, Joanne B. Fertig, Megan L. Ryan, Daniel E. Falk, Howard B. Moss, Robert B. Huebner, Antonio Noronha	168
16	The Alcohol Clinical Trials Initiative (ACTIVE): Purpose and Goals for Assessing Important and Salient Issues for Medications Development in Alcohol Use Disorders 2011 ·Neuropsychopharmacology ·(unknown), Raymond F. Anton, Raye Z. Litten, Daniel E. Falk, Joseph Palumbo, Raymond T. Bartus, R.L. Robinson, Henry R. Kranzler, Thomas R. Kosten, Roger E. Meyer, Charles P. O’Brien, Karl Mann, Didier Meulien	25
17	A Double‐Blind, Placebo‐Controlled Trial to Assess the Efficacy of Quetiapine Fumarate XR in Very Heavy‐Drinking Alcohol‐Dependent Patients 2011 ·Alcoholism Clinical and Experimental Research ·Raye Z. Litten, Joanne B. Fertig, Daniel E. Falk, Megan L. Ryan, Margaret E. Mattson, Joseph F. Collins, (unknown), Domenic A. Ciraulo, Alan I. Green, Bankole A. Johnson, Helen M. Pettinati, Robert Swift, Maryam Afshar, Mary F. Brunette, Nassima Ait‐Daoud Tiouririne, Kyle M. Kampman, Robert L. Stout, (unknown)	74
18	Percentage of Subjects With No Heavy Drinking Days: Evaluation as an Efficacy Endpoint for AlcoholClinical Trials 2010 ·Alcoholism Clinical and Experimental Research ·Daniel E. Falk, Xin Qun Wang, Lei Liu, Joanne B. Fertig, Margaret E. Mattson, Megan Ryan, Bankole A. Johnson, Robert L. Stout, Raye Z. Litten	148
19	Age of onset and temporal sequencing of lifetime DSM-IV alcohol use disorders relative to comorbid mood and anxiety disorders 2008 ·Drug and Alcohol Dependence ·Daniel E. Falk, Hsiao‐ye Yi, Michael E. Hilton	117
20	An Epidemiologic Analysis of Co-Occurring Alcohol and Tobacco Use and Disorders 2006 ·Alcohol research ·Daniel E. Falk, Hsiao‐ye Yi, Susanne Hiller-Sturmhöfel	98

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact